Choi YL - Search Results

1

Clinical benefit and residual kidney function of en bloc nephrectomy for perirenal retroperitoneal sarcoma.

Cho CW, Lee KW, Park H, Kim HJ, Park JB, Choi YL, Yu JI, Lee SJ, Choi DI, Kim SJ. Cho CW, et al. Among authors: choi yl, choi di. Asia Pac J Clin Oncol. 2018 Oct;14(5):e465-e471. doi: 10.1111/ajco.12769. Epub 2017 Oct 18. Asia Pac J Clin Oncol. 2018. PMID: 29044883

2

Liposarcoma: exploration of clinical prognostic factors for risk based stratification of therapy.

Kim HS, Lee J, Yi SY, Jun HJ, Choi YL, Ahn GH, Seo SW, Lim DH, Ahn YC, Park JO, Kim SJ. Kim HS, et al. Among authors: choi yl. BMC Cancer. 2009 Jun 26;9:205. doi: 10.1186/1471-2407-9-205. BMC Cancer. 2009. PMID: 19558664 Free PMC article.

3

Angiosarcoma arising within a long-standing cystic lesion of the adrenal gland: a case report.

Sung JY, Ahn S, Kim SJ, Park YS, Choi YL. Sung JY, et al. Among authors: choi yl. J Clin Oncol. 2013 Mar 20;31(9):e132-6. doi: 10.1200/JCO.2012.44.0800. Epub 2013 Jan 28. J Clin Oncol. 2013. PMID: 23358968 No abstract available.

4

Surgical outcome of desmoid tumors: adjuvant radiotherapy delayed the recurrence, but did not affect long-term outcomes.

Shin SH, Ko KR, Cho SK, Choi YL, Seo SW. Shin SH, et al. Among authors: choi yl. J Surg Oncol. 2013 Jul;108(1):28-33. doi: 10.1002/jso.23343. Epub 2013 Apr 26. J Surg Oncol. 2013. PMID: 23625342

5

High level of CDK4 amplification is a poor prognostic factor in well-differentiated and dedifferentiated liposarcoma.

Lee SE, Kim YJ, Kwon MJ, Choi DI, Lee J, Cho J, Seo SW, Kim SJ, Shin YK, Choi YL. Lee SE, et al. Among authors: choi yl, choi di. Histol Histopathol. 2014 Jan;29(1):127-38. doi: 10.14670/HH-29.127. Epub 2013 Jul 15. Histol Histopathol. 2014. PMID: 23852861

6

Establishment of primary xenograft model from newly characterized patient extrauterine carcinosarcoma.

Lee HJ, Choi HJ, Yang HM, Kim YM, Lee J, Chio D, Kim B, Choi YL, Kim SJ. Lee HJ, et al. Among authors: choi yl, choi hj. Int J Gynecol Cancer. 2013 Nov;23(9):1552-60. doi: 10.1097/01.IGC.0000434105.98035.c7. Int J Gynecol Cancer. 2013. PMID: 24172092

7

Aberrant CDK4 amplification in refractory rhabdomyosarcoma as identified by genomic profiling.

Park S, Lee J, Do IG, Jang J, Rho K, Ahn S, Maruja L, Kim SJ, Kim KM, Mao M, Oh E, Kim YJ, Kim J, Choi YL. Park S, et al. Among authors: choi yl. Sci Rep. 2014 Jan 10;4:3623. doi: 10.1038/srep03623. Sci Rep. 2014. PMID: 24406431 Free PMC article.

8

CDK4 amplification predicts recurrence of well-differentiated liposarcoma of the abdomen.

Lee S, Park H, Ha SY, Paik KY, Lee SE, Kim JM, Park JB, Kwon CH, Joh JW, Choi YL, Kim SJ. Lee S, et al. Among authors: choi yl. PLoS One. 2014 Aug 14;9(8):e99452. doi: 10.1371/journal.pone.0099452. eCollection 2014. PLoS One. 2014. PMID: 25121597 Free PMC article.

9

Gankyrin is a predictive and oncogenic factor in well-differentiated and dedifferentiated liposarcoma.

Hwang JA, Yang HM, Hong DP, Joo SY, Choi YL, Park JH, Lazar AJ, Pollock RE, Lev D, Kim SJ. Hwang JA, et al. Among authors: choi yl. Oncotarget. 2014 Oct 15;5(19):9065-78. doi: 10.18632/oncotarget.2375. Oncotarget. 2014. PMID: 25238053 Free PMC article.

10

Pazopanib, a novel multitargeted kinase inhibitor, shows potent in vitro antitumor activity in gastric cancer cell lines with FGFR2 amplification.

Kim ST, Jang HL, Lee SJ, Lee J, Choi YL, Kim KM, Cho J, Park SH, Park YS, Lim HY, Yashiro M, Kang WK, Park JO. Kim ST, et al. Among authors: choi yl. Mol Cancer Ther. 2014 Nov;13(11):2527-36. doi: 10.1158/1535-7163.MCT-14-0255. Epub 2014 Sep 23. Mol Cancer Ther. 2014. PMID: 25249557

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

537 results

Search Page

Filters